Bacterial lysate add‐on therapy to reduce exacerbations in severe asthma: A double‐blind placebo‐controlled trial
Open Access
- 6 August 2021
- journal article
- research article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 51 (9) , 1172-1184
Abstract
Background: Asthma exacerbations are frequently induced by respiratory tract infections (RTIs). Bacterial lysates have been described to possess immune‐modulatory effects and reduce RTIs as well as asthma symptoms in children. However, whether bacterial lysates have similar effects in adult asthma patients is unknown.Aims: To reduce asthma exacerbations by add‐on bacterial lysate therapy in adults with severe asthma and to characterize the clinical and immune‐modulatory effects of this treatment.Methods: Asthma patients (GINA 4) with ≥2 annual exacerbations in the previous year were included. The intervention regimen consisted of OM‐85/placebo for 10 consecutive days per month for 6 months during two winter seasons. Primary end‐point was the number of severe asthma exacerbations within 18 months. The study was approved by the national and local ethical review board and registered in the Dutch Trial Registry (NL5752). All participants provided written informed consent.Results: Seventy‐five participants were included (38 OM‐85; 37 placebo). Exacerbation frequencies were not different between the groups after 18 months (incidence rate ratio 1.07, 95%CI [0.68–1.69], p = 0.77). With the use of OM‐85, FEV1% increased by 3.81% (p = 0.04) compared with placebo. Nasopharyngeal swabs taken during RTIs detected a virus less frequently in patients using OM‐85 compared to placebo (30.5% vs. 48.0%, p = 0.02).In subjects with type 2 inflammation adherent to the protocol (22 OM‐85; 20 placebo), a non‐statistically significant decrease in exacerbations in the OM‐85 group was observed (IRR = 0.71, 95%CI [0.39–1.26], p = 0.25). Immune‐modulatory effects included an increase in several plasma cytokines in the OM‐85 group, especially IL‐10 and interferons. Peripheral blood T‐ and B cell subtyping, including regulatory T cells, did not show differences between the groups.Conclusion: Although OM‐85 may have immune‐modulatory effects, it did not reduce asthma exacerbations in this heterogeneous severe adult asthma group. Post hoc analysis showed a potential clinical benefit in patients with type 2 inflammation.Keywords
Funding Information
- European Society for Paediatric Infectious Diseases
This publication has 32 references indexed in Scilit:
- Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equationsEuropean Respiratory Journal, 2012
- Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: A meta-analysisPulmonary Pharmacology & Therapeutics, 2012
- Clinical Impact of RT-PCR for Pediatric Acute Respiratory Infections: A Controlled Clinical TrialPediatrics, 2011
- The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airwaysMucosal Immunology, 2011
- The immunostimulant OM-85 BV prevents wheezing attacks in preschool childrenJournal of Allergy and Clinical Immunology, 2010
- Boosting airway T-regulatory cells by gastrointestinal stimulation as a strategy for asthma controlMucosal Immunology, 2010
- Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of viewRespiratory Medicine, 2008
- Immunostimulants for preventing respiratory tract infection in childrenCochrane Database of Systematic Reviews, 2006
- ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005American Journal of Respiratory and Critical Care Medicine, 2005
- Immunostimulation with OM-85 in Children with Recurrent Infections of the Upper Respiratory TractChest, 2002